Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16422495 | 0.85 | CTSD (0.54) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL9531212 | 0.84 | SLC18A3 (0.66) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL2776534 | 0.84 | CTSD (0.55) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL9531228 | 0.84 | SLC18A3 (0.66) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL2776529 | 0.84 | CTSD (0.55) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL9531221 | 0.84 | SLC18A3 (0.66) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL8245028 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4GBA1SLC18A3CTSD | |
| SCHEMBL22273230 | 0.81 | SLC18A3 (0.56) | SLC6A2SLC6A4SLC18A3CTSDEBP | |
| SCHEMBL22252483 | 0.81 | SLC18A3 (0.56) | SLC6A2SLC6A4SLC18A3CTSDEBP | |
| SCHEMBL20687903 | 0.81 | SLC18A3 (0.56) | SLC6A2SLC6A4SLC18A3CTSDEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |